- Home
- IVR vs XERS Comparison
IVR vs XERS Comparison
Compare IVR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- XERS
- Stock Information
- Founded
- IVR 2008
- XERS 2005
- Country
- IVR United States
- XERS United States
- Employees
- IVR N/A
- XERS N/A
- Industry
- IVR Real Estate Investment Trusts
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- IVR Real Estate
- XERS Health Care
- Exchange
- IVR Nasdaq
- XERS Nasdaq
- Market Cap
- IVR 515.0M
- XERS 500.2M
- IPO Year
- IVR 2009
- XERS 2018
- Fundamental
- Price
- IVR $8.18
- XERS $3.34
- Analyst Decision
- IVR Buy
- XERS Buy
- Analyst Count
- IVR 2
- XERS 3
- Target Price
- IVR N/A
- XERS $4.87
- AVG Volume (30 Days)
- IVR 1.8M
- XERS 1.3M
- Earning Date
- IVR 02-20-2025
- XERS 03-05-2025
- Dividend Yield
- IVR 19.45%
- XERS N/A
- EPS Growth
- IVR N/A
- XERS N/A
- EPS
- IVR 1.23
- XERS N/A
- Revenue
- IVR $102,893,000.00
- XERS $187,361,000.00
- Revenue This Year
- IVR N/A
- XERS $24.27
- Revenue Next Year
- IVR $8.53
- XERS $18.57
- P/E Ratio
- IVR $6.68
- XERS N/A
- Revenue Growth
- IVR 654.96
- XERS 22.72
- 52 Week Low
- IVR $7.48
- XERS $1.69
- 52 Week High
- IVR $9.97
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- IVR 51.78
- XERS 49.66
- Support Level
- IVR $7.48
- XERS $3.14
- Resistance Level
- IVR $8.29
- XERS $3.60
- Average True Range (ATR)
- IVR 0.19
- XERS 0.17
- MACD
- IVR 0.02
- XERS -0.02
- Stochastic Oscillator
- IVR 85.80
- XERS 37.74
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.